Topiramate has been one of the most widely prescribed migraine preventives for decades, not because it works best, but largely because it causes weight loss. That side effect made it acceptable to patients and doctors willing to overlook a long list of others: brain fog, memory difficulties, kidney stones, osteoporosis, and birth defects.
The birth defect risk deserves more attention than it gets. Most migraine sufferers are young women of childbearing age, and half of all pregnancies are unplanned. Topiramate is a known teratogen. I think every woman of childbearing age prescribed this drug must be informed about that risk before she fills the prescription. I stopped using it as a first, second, or third choice years ago.
A new study from the Leiden Headache Center confirms that it was the right call.
Candesartan is a blood pressure medication in the ARB family. Beta blockers, the oldest preventive migraine drugs, also work through the cardiovascular system, but they slow the heart rate and make exercise harder. Candesartan does not do that.
In a real-world cohort of 661 patients, 67% of those on topiramate stopped taking it within six months. For candesartan, 30%. The 50% responder rate: 47% for candesartan versus 29% for topiramate.
Topiramate is FDA-approved for migraine prevention. Candesartan is not. According to standard evidence-based medicine guidelines, topiramate comes first. But a drug that two-thirds of patients quit within six months is not preventing anyone’s migraines. FDA approval tells you which drugs got studied in industry-funded trials. It does not tell you which ones patients can actually tolerate.
Candesartan is inexpensive, well-tolerated, and now backed by real-world data showing it outperforms one of the most commonly prescribed migraine preventives on both counts. The study authors say guidelines should be revised. I agree.
